NR-507 Week 5 Case Study Discussion: Part One, Two

NR-507 Week 5 Case Study Discussion: Part One, Two

NR-507 Week 5 Case Study Discussion: Part One, Two

Permalink: https://nursingbay.com/nr-507-week-5-ca…ion-part-one-two/

NR-507 Week 5 Case Study Discussion: Part One

Ms. Blake is an older adult with diabetes and has been too ill to get out of bed for 2 days. She has had a severe cough and has been unable to eat or drink during this time. She has a history of Type I diabetes. On admission her laboratory values show:

CLICK HERE TO ORDER NR-507 Week 5 Case Study Discussion: Part One, Two

  1. What is the etiology of Diabetic Ketoacidosis?
  2. Describe the pathophysiological process of Diabetic Ketoacidosis?
  3. Identify the hallmark symptoms of Diabetic Ketoacidosis?
  4. Identify any abnormal lab results provided in the case and explain why these would be abnormal given the patient’s condition.
  5. What teaching would you provide this patient to avoid heart failure symptoms?
  6. What teaching would you provide this patient to avoid diabetic ketoacidosis?

Journal of the Endocrine Society, Volume 4, Issue Supplement_1, April-May 2020, SAT-672, https://doi.org/10.1210/jendso/bvaa046.180

NR 507 Week 5 Case Study Discussion: Part Two

A three-month-old baby boy comes into your clinic with the main complaint that he frequently vomits after eating. He often has a swollen upper belly after feeding and acts fussy all the time. According to his parents, the vomiting has become more frequent this past week and he is beginning to lose weight. After careful history taking, a thorough physical exam and diagnostic work-up, the patient is …. with pyloric stenosis.

  1. What is the etiology of pyloric stenosis?
  2. Describe in detail the pathophysiological process of pyloric stenosis.
  3. Identify hallmark signs identified from the physical exam and presenting symptoms. What diagnostic tests would help to confirm the diagnosis of pyloric stenosis?
  4. Describe the pathophysiology of complications of pyloric stenosis.
  5. What teaching would you provide this patient/parents regarding pyloric stenosis?

NR507 Week 6 Recorded Disease Process Presentation

The Recorded Disease Process Presentation assignment must be submitted for faculty grading by Sunday, 11:59 p.m. MT at the end of Week 6. The guidelines and grading rubric are located in the Course Resource section.

This assignment will follow the late assignment policy specified in the course syllabus.

Reminder: The Recorded Disease Process Presentation assignment must also be uploaded into the discussion area by Tuesday, 11:59 p.m. MT of Week 6. All questions must be addressed by Sunday, 11:59 p.m. MT at the end of Week 6.

Week 6: Recorded Disease Process Presentation Peer Review

Please upload your recorded Disease Process PowerPoint presentations to this area by Tuesday, 11:59 p.m. MT. See the Disease Process Presentation Peer Review Guidelines and Rubric located in the Course Resource section for specific information.

Students are to review at least one peer’s recorded presentation and respond to it by Thursday, 11:59 p.m. MT using the Disease Process Peer Review Guidelines.

Presenters are also required to monitor comments and questions from peers and faculty about their presentations and respond appropriately. Make sure to respond to all faculty questions. All responses are due by Sunday 11:59 p.m. MT.

Recorded Disease Process Presentation

  1. Discuss the risk factors and the connection to the etiology of the initial injury to the cell/tissue/organ.

The main risk factor for cystic fibrosis is two parents that are carriers of abnormal genes and then pass the genes on to their children. However, there are other risk factors such as environment, lifestyle, and age that contribute to the severity and progression of cystic fibrosis. Cystic fibrosis gene mutations are divided into classes based on how damaged the CFTR protein function is. Classes, I, II, and III are generally more severe causing “classic CF (Cutting, 2015).  Classes IV and V are usually milder. Also, other genes called modifier genes can affect a person’s symptoms and outcome (Cutting, 2015).  Environment and lifestyle: People with CF need to consume a very large number of calories to maintain weight and grow, which can be difficult to achieve. Physical activity is also important to help keep lungs healthy. People with CF should not smoke or be exposed to secondhand smoke, as it will worsen lung disease. Patients should also be careful with alcohol intake and avoid it altogether if they have liver disease.  Patients with CF usually have their condition worsen as they age.

References

Cutting, G. R. (2015). Cystic fibrosis genetics: from molecular understanding to clinical application. Nature Reviews Genetics16(1), 45-56. doi:10.1038/nrg3849

CLICK HERE TO ORDER NR-507 Week 5 Case Study Discussion: Part One, Two

Rubric

NR507 Week 6 Recorded Disease Process Presentation

NR507 Week 6 Recorded Disease Process Presentation
Criteria Ratings Pts
This criterion is linked to a Learning Outcome Application of Course Knowledge
70.0 ptsExceptional- The recorded presentation includes clear presentation of all required concepts: -Introduction of disease with brief definition and description. -Risk factors with link to etiology provided. -Implications of health care provider in disease prevention. -Shows progression from the initial injury to the defect in the tissue, organ, and system functioning. – Links changes in the tissue, organ, and system functioning to the initial presenting signs and symptoms seen in primary care of the disease. – Provides a brief description of how the disease is diagnosed. – Provide a brief description of the pharmacological and non-pharmacological interventions used to treat and manage the disease. All concepts are presented with logical thought process. 61.0 ptsExceeds- The recorded presentation includes clear presentation of all required concepts and linkages, but may lack some applicability to topic or misses one criteria in some way. 57.0 ptsMeets- The recorded presentation has limited perspective, unclear linkages, insights and/or applicability to topic or does not meet one or more of the criteria of the assignment. 28.0 ptsNeeds Improvement- The recorded presentation contains inaccurate information and is not consistent with current practice. No clear linkages provided. Analysis is minimal. 0.0 ptsDeveloping- The recorded presentation offers no insight or application to the assignment or course content.
70.0 pts
This criterion is linked to a Learning Outcome Support from Evidence-Based Practice (EBP)
60.0 ptsExceptional- Scholarly literature is present throughout the presentation. Guidelines regarding disease prevention and pharmacological and non-pharmacological interventions are addressed and clearly analyzed. 52.0 ptsExceeds- Where applicable in in the recorded presentation, analysis is partially supported by evidence from appropriate sources published within the last 5 years. In-text citations and full references are provided. Evidence-based, peer reviewed journal article cited but may not fully support disease prevention and pharmacological and non-pharmacological interventions. 49.0 ptsMeets- Where applicable in the recorded presentation, analysis is partially supported by evidence. Sources may not be scholarly in nature or may be older than 5 years. Guidelines are not used. In-text citations and/or full references may be incomplete or missing. 24.0 ptsNeeds Improvement- Citations to non-scholarly websites given as rationale to support disease prevention and pharmacological and non-pharmacological interventions. 0.0 ptsDeveloping- Presentation contains no evidence-based practice reference or citation.
60.0 pts
This criterion is linked to a Learning Outcome Summary of Disease Process
50.0 ptsExceptional- Summarizes the disease using concise statements that reflect all content covered in the presentation. Implications for practice addressed. 44.0 ptsExceeds- Summarizes the disease using concise statements that reflect all content covered in the presentation. Implications for practice not clearly evident. 41.0 ptsMeets- Summarizes the disease using concise statements with some content not reflected in the summary. Implications for practice not clearly evident or missing. 20.0 ptsNeeds Improvement- Summary of the disease process is lacking concise statements and all content not reflected in the summary. Implications for practice not addressed or not clearly evident. 0.0 ptsDeveloping- No summary of the disease process provided. Implications for practice not addressed.
50.0 pts
This criterion is linked to a Learning Outcome Professionalism/ Organization
10.0 ptsExceptional- The recorded presentation has clear audio and video. The content flows in a logical, smooth manner. Verbal pauses are limited or absent. Student speaks in a clear cadence and speed. 9.0 ptsExceeds- The recorded presentation is lacking 1-2 components from the 50 point criteria 8.0 ptsMeets- The recorded presentation is lacking 3-4 components from the 50 point criteria. 4.0 ptsNeeds Improvement- Presentation presents findings that are sometimes unclear to follow and may not always be relevant to topic and concepts are difficult to follow. 0.0 ptsDeveloping- The audio/video is hard to hear/see. Slides contain lengthy content (student reading from slides). Presentation style lacks flow of ideas and thoughts.
10.0 pts
This criterion is linked to a Learning Outcome Grammar, Syntax, Spelling, & Punctuation
10.0 ptsExceptional- Grammar, spelling, and/or punctuation are accurate, or with zero to one error. 9.0 ptsExceeds- Two to four errors in grammar, spelling, and syntax noted. 8.0 ptsMeets- Five to seven errors in grammar, spelling, and syntax noted. 4.0 ptsNeeds Improvement- Eight to nine errors grammar, spelling, and syntax noted. 0.0 ptsDeveloping- Post contains ten or greater errors grammar, spelling, and/or punctuation or repeatedly makes the same errors after faculty feedback.
10.0 pts
Total Points: 200.0

NR 507 Final Exam Study Guide: Chapters 1-5, 11-14, 16-20, 21-25, 27-3-33, 34-39, 40-47

  1. Types of immunity-e.g. innate, active, etc (ch 7 ,191)
  2. Alveolar ventilation/perfusion- (ch, 34,pg 1238)
  3. Dermatologic conditions e.g. pityriasis rosea (ch46, pg 1630/1631)
  4. Croup (C 36,pg 1294)-
  5. Types of anemia (ch 28,pg 987-1002)
  6. The inflammatory process upon injury ( ch 7)
  7. GI symptoms resulting in heart burn( ch 41, pg 1429- 1466)
  8. Pulmonary terminology such as dyspnea, orthopnea, etc ( ch 35, pg 1249)
  9. Complications of gastric resection surgery (c 41, pg 1439)
  10. Dermatology terminology-macules, nevi, etc ( ch 46, pg 1620)
  11. Chicken pox ( c 46,pg 1659)
  12. Maternal immune system- (ch 8 & 9, pg 259-276)
  13. Candidiasis exacerbation ( ch 10,313)
  14. Carbuncles (ch 46, pg 1635
  15. Terms such as hypochromic, macrocytic, microcytic, etc ( ch 28 pg 983 ) see chart above also it will not move for me
  16. Antibodies, IgG, IgA, etc- (ch 8, pg 229)
  17. Skin cancer ( ch 46 pg, 1641)
  18. Parts of the heart in terms of function, such as pericardium ( ch 31, p 1085)
  19. Congenital heart defects (ch 33pg 1200)
  20. GI symptoms of conditions such as pyloric stenosis, hiatal hernia, ulcerative colitis- (ch 41 pg 148,1429,1440)
  21. Skin cancer lesions ( ch 46, pg 1641)
  22. Gastroesophageal reflux disease- (c 41, p 1439)
  23. Hypersensitivity reaction ( ch 9 ,p262)-
  24. Congenital intrinsic factor deficiency( ch 28, 988)
  25. Acid base imbalance – (ch 3 p 1236)
  26. Acute epiglottitis(ch 36,pg 1296)
  27. Types of gastric ulcers-signs and symptoms, characteristics ( ch 41, pg 1437-1438)
  28. Lupus (ch 9,p277)
  29. General adaptation syndrome (ch 11,p 339)
  30. Ventilation/perfusion ratio ( ch 34, pg 1238-1239)
  31. Bile salt deficiencies ( ch 41,pg 1440)
  32. Clonal selection (ch 12, pg373)
  33. Obstructive sleep apnea (ch 16,pg 504)
  34. Large bowel obstruction (ch 41,pg 1431)
  35. Vaginal candidiasis (ch 24,pg 874)
  36. Folate deficiency (ch 2,pg 67)
  37. Pancreatic insufficiency (ch 41 pg 1439)
  38. Types of fractures- ( ch 44,pg 1541-1542)
  39. Genetic disorders such as Down Syndrome, Turner Syndrome, etc ( ch 4 pg 146-150)
  40. Glaucoma- ( ch 16, pg 510)
  41. Cervical immunoglobulin- (ch 23, pg 775)
  42. Concept of pain ( ch 16 p 485)
  43. Autosomal dominant diseases ( ch 4 pg 153)
  44. Congenital murmurs ( ch 32 pg 1168-1170)
  45. Lactose intolerance (CH 42,PG 1500)-
  46. Angiotensin-renin system ( ch 5, ch 37 pg 1327)
  47. AIDS (ch 10pg 322)
  48. Carcinoma ( ch 12 pg 363 )
  49. Hormonal regulation of calcium ( ch 3 pg 119)
  50. Neural tube defect- (ch 20,pg 663)and )ch 5,pg 167)
  51. Types of hormones- ( google)
  52. Glycoprotein (ch 8 ,pg 229)
  53. Kidney stones (Ch 38, pg 1343)
  54. Type 2 diabetes ( ch 22, pg 739)
  55. Pituitary hormone secretion- (ch 21 pg 696-698)
  56. Signs of breast cancer ( ch 24, pg 873)
  57. Alzheimer’s disease- ( ch5, p 178)
  58. Guillain-Barre Syndrome (ch 17, p 622)
  59. Sympathetic/parasympathetic nervous system ( ch 11 pg 344)
  60. ACTH- (c 11,pg 339)
  61. Bartholin glands (C24,pg 920)
  62. Gonococcal disease (c 26,pg 919)
  63. Glomerulonephritis-( chap 38)
  64. Small patent ductus arteriosus ( ch 33, pg 1202)
  65. Risk factors for hypertension- ( ch 32, pg 1132-1140)
  66. Loss of language and/or comprehension-such as terms-aphasia, etc. ( ch 17, pg 539)
  67. Chronic inflammatory joint disease ( ch 44, pg 1568-1578)
  68. Male and female sex hormone production ( ch 23 pg 726-791)
  69. Endogenous antigen (c 8,pg 245)
  70. Genital warts- (ch 26, pg 934)
  71. Pancreatic enzymes ( c 40,pg 1415)
  72. Process of muscle contraction( c 43,pg 1533)
  73. Cervical dysplasia (C 24,pg 825)
  74. Consanguinity- (c4,pg 156)
  75. Nephrotic syndrome ( chap 38)
  76. NR-507 Week 5 Case Study Discussion: Part One, Two
Get a 10 % discount on an order above $ 100
Use the following coupon code :
nursingbay